Redx Pharma is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high unmet medical need, in cancer and fibrosis. By improving the characteristics of existing drug classes, we aim to create differentiated, novel drugs.
Redx has an established portfolio of proprietary drug programs that it is developing alone and in partnership with leading pharmaceutical companies and healthcare bodies. Our Porcupine inhibitor, RXC004, is advancing into Phase I clinical development for gastric, biliary and pancreatic cancers. It is our aim that our discoveries will provide a pipeline of potential assets to complement and combine with the drug portfolios of larger and emerging pharmaceutical companies.